

# Journal of Visualized Experiments

## Purification of H3 and H4 histone proteins and quantification of acetylated histone marks in cells and brain tissue --Manuscript Draft--

Article Type:	Invited Methods Article - JoVE Produced Video
Manuscript Number:	JoVE58648R3
Full Title:	Purification of H3 and H4 histone proteins and quantification of acetylated histone marks in cells and brain tissue
Keywords:	epigenetics; core histones; histone modifications; acetylation; deacetylation; histone code; post-translational modifications (PTMs)
Corresponding Author:	C Dr. Volmar
Corresponding Author's Institution:	
Corresponding Author E-Mail:	CVolmar@med.miami.edu
Order of Authors:	Karolina J Janczura Claude-Henry Volmar Claes Wahlestedt
Additional Information:	
Question	Response
Please indicate whether this article will be Standard Access or Open Access.	Open Access (US\$4,200)
Please indicate the <b>city, state/province, and country</b> where this article will be <b>filmed</b> . Please do not use abbreviations.	Miami, Florida, USA

**TITLE:**

**Purification of H3 and H4 Histone Proteins and the Quantification of Acetylated Histone Marks in Cells and Brain Tissue**

**AUTHORS AND AFFILIATIONS:**

Karolina J. Janczura<sup>1,2</sup>, Claude-Henry Volmar<sup>1,2</sup>, Claes Wahlestedt<sup>1,2</sup>

<sup>1</sup>University of Miami Miller School of Medicine, Department of Psychiatry & Behavioral Sciences, Miami, FL, United States of America

<sup>2</sup>University of Miami Miller School of Medicine, Center for Therapeutic Innovation, Miami, FL, United States of America

**Corresponding Authors:**

Claes Wahlestedt (cwahlestedt@med.miami.edu)

Tel.: +1-305-243-1367

Claude-Henry Volmar (cvolmar@med.miami.edu)

Tel.: +1-305-243-1209

**E-mail Address of the Co-author:**

Karolina J. Janczura (kjj17@med.miami.edu)

**KEYWORDS:**

Epigenetics, core histones, histone modifications, acetylation, deacetylation, histone code, posttranslational modifications (PTMs)

**SUMMARY:**

The purpose of this article is to provide a comprehensive, systematic guide to the efficient purification of histones H3 and H4 and the quantification of acetylated histone residues.

**ABSTRACT:**

In all eukaryotic organisms, chromatin, the physiological template of all genetic information, is essential for heredity. Chromatin is subject to an array of diverse posttranslational modifications (PTMs) that mostly occur in the amino termini of histone proteins (*i.e.*, histone tail) and regulate the accessibility and functional state of the underlying DNA. Histone tails extend from the core of the nucleosome and are subject to the addition of acetyl groups by histone acetyltransferases (HATs) and the removal of acetyl groups by histone deacetylases (HDACs) during cellular growth and differentiation. Specific acetylation patterns on lysine (K) residues on histone tails determine a dynamic homeostasis between transcriptionally active or transcriptionally repressed chromatin by (1) influencing the core histone assembly and (2) recruiting synergistic or antagonistic chromatin-associated proteins to the transcription site. The fundamental regulatory mechanism of the complex nature of histone tail PTMs influences the majority of chromatin-templated processes and results in changes in cell maturation and differentiation in both normal and pathological development. The goal of the current report is to provide novices with an efficient

method to purify core histone proteins from cells and brain tissue and to reliably quantify acetylation marks on histones H3 and H4.

## INTRODUCTION:

The term epigenetics refers to heritable changes in gene activity that occur independently from changes in the DNA sequence<sup>1,2</sup>. Gene transcription and repression are determined by (1) the accessibility of the chromosomal DNA wrapped around an octamer of core histone proteins (two copies each of H2A, H2B, H3, and H4) and by (2) the availability of transcription factors and scaffold proteins recruited to specific promoter sites<sup>3,4</sup>. Gene transcription is regulated by enzyme-mediated modifications of specific DNA promoter sites and the PTMs of histone tails<sup>5-7</sup>. The N-termini of histone H3 and H4 are among the most highly conserved sequences known in eukaryotic organisms<sup>3</sup>, and their posttranslational modifications have been extensively documented to play a central role in determining chromatin structure and function<sup>8,9</sup>. PTMs at the histone tails (*i.e.*, acetylation, methylation, phosphorylation, and ubiquitination) change the interaction potential of the tails, influence the structural state and folding of chromatin fiber, and thereby, regulate DNA accessibility and processing<sup>4,10-12</sup>. Acetyl groups are added to and removed from K residues on histone tails by a set of specific histone-interacting epigenetic enzymes, namely HATs and HDACs, respectively<sup>13</sup>. For example, the acetylation of histone H4 at lysine 12 (H4K12ac) has been previously shown to activate the transcription of genes related to memory acquisition and consolidation<sup>14</sup>. Additionally, several lines of evidence suggest that the enzyme-mediated epigenetic control of gene transcription is a crucial aspect of healthy cellular growth and differentiation<sup>6,15</sup>. Alternation in the epigenetic regulation of gene expression, either by epigenetic modifications of DNA or by a mutation of the epigenetic enzymes themselves, has been shown to be dysregulated in human diseases where change in a particular gene activity is a hallmark of the pathology (*e.g.*, cancer)<sup>6,16,17</sup>. Thus, the evaluation of changes in core histone PTMs is emerging as a high-value target for potential therapeutic interventions. However, determining the abundance, interacting partners, and specific roles of histones PTMs has been proven challenging<sup>18</sup>.

In the current report, an optimized, medium-throughput strategy to purify core histones from cells and brain tissues in a single fraction, and a complete protocol for the quantification of histones H3 and H4 PTMs is described. Of note, although currently published acid-based purification techniques and antibody-based histone detection strategies have been widely adopted for histone characterization, they lack descriptive details regarding critical steps of the procedure, thus hindering quick and replicable histone extraction and quantification. For example, the processing of cell extract and tissue biopsies requires different tools and technologies for successful extraction. Moreover, the optimized protocol presented in the current manuscript demonstrates a practical, medium-throughput approach. Core histones are extracted as a single, pure fraction, which enables reliable downstream antibody-mediated PTM detection without any interference from impurities. Furthermore, in the current manuscript, the challenges regarding histone detection due to their small molecular weight have been circumvented. Typically, the lack of compatibility between purification, quantification, and gel electrophoresis protocols hinder scientists from obtaining replicable and conclusive results. Here,

an optimized workflow to purify core histones from cells and tissue and prepare them for downstream PTM analyses *via* western blot is presented.

The current protocol enables the purification of core histone proteins while preserving their native posttranslational modifications (*i.e.*, acetylation, methylation, and phosphorylation). **Figure 1** depicts the timeline of the histone purification protocol.

## **PROTOCOL:**

All mice were housed in a humidity- and temperature-controlled, AAALAC-accredited animal facility at the University of Miami Miller School of Medicine. All experiments were approved by the University of Miami Miller School of Medicine Institutional Animal Care and Use Committee (IACUC) and conducted according to specifications of the NIH.

### **1. Preparation of the Sample Extract**

#### **1.1. Adherent cells**

**1.1.1.** Plate cells in 10 cm dishes in the appropriate culture media ( $1 \times 10^6$  to  $1 \times 10^9$  cells per dish for cell lines, such as BV2, HEK-293, and SH-SY5Y, but  $\sim 1 \times 10^{15}$  cells per dish for primary cells, such as primary cortical neurons). Assure that the cells are equally distributed on the entire surface of the plate and allow the cells to grow for 48 h to reach  $\sim 100\%$  confluence ( $37^\circ\text{C}$ ,  $5\% \text{CO}_2$ ).

**1.1.2.** Once the cells have reached the desired confluency, gently aspirate the culture media and wash the cells 2x with prewarmed serum-free media under a tissue culture hood.

**1.1.3.** Aspirate the serum-free media from the dish and add 1 mL of ice-cold extraction buffer (0.4 M sulfuric acid, 1 mM KCl, 1 mM  $\text{MgCl}_2$ , 50 mM Tris-HCl [pH 8.0] and 1x protease inhibitor cocktail) to each dish.

**1.1.4.** Use a plastic cell scraper to collect all cells in the extraction buffer (by scraping) and transfer them to a 1.5 mL labeled tube with a 1,000  $\mu\text{L}$  pipette. Pipet the cells up and down 3x to facilitate homogenization.

**1.1.5.** Close all tubes and immediately put them on ice.

#### **1.2. Brain tissue**

**1.2.1.** If frozen tissue is being used, place the tissue in a prechilled 1.5 mL tube and briefly thaw it on ice. If fresh tissue is being used, proceed immediately to step 1.2.2.

**NOTE:** The current protocol describes procedures using frozen mouse brain and mouse prefrontal cortex samples.

1.2.2. Homogenize the tissue using a handheld Dounce homogenizer using the appropriate amount of extraction buffer and the recommended number of strokes (**Table 1**). To avoid excessive chromatin shredding, do not exceed the number of recommended strokes.

1.2.3. Using a single channel 1,000  $\mu$ L pipette, transfer the homogenate to a prechilled 1.5 mL tube. Close all tubes and immediately put them on ice.

## **2. Preparation of the Crude Histone Extract**

2.1. Place the 1.5 mL tubes containing the cells or tissue suspended in extraction buffer on a rotating platform and rotate at 15 rpm at 4 °C to allow the extraction of crude histones.

NOTE: The extraction time may vary for different cell and tissue types and must be optimized for each procedure. The current protocol presents results obtained following 15 min, 2 h, and 24 h of extraction (**Figure 2**, **Figure 3**, **Figure 4**, and **Figure 5**).

2.2. Prechill the microcentrifuge to 4 °C. After the desired extraction time has passed, centrifuge the tubes at maximum speed for 10 min at 4 °C.

2.3. Transfer the supernatant including the crude histones to a new, prechilled 1.5 mL tube. Discard the pellet.

2.4. Store the supernatant at -80 °C (the extraction can be stopped at this step, see “Stop step” in **Figure 1**) or immediately proceed to the next step.

2.5. Neutralize the crude histones with a 1/4 volume of 5x neutralization buffer (e.g., add 250  $\mu$ L of 5x neutralization buffer to 1 mL of crude histones). Mix well by pipetting up and down 6x.

2.6. Check the pH of the mixture with pH strips. Adjust accordingly by adding more neutralization buffer to reach a pH of 7.

2.7. Evaluate the presence of histone and nonhistone protein in the crude histone extract as follows (**Figure 2**).

2.7.1. Add 37.5  $\mu$ L of the sample to 12.5  $\mu$ L of 4x (Laemmli) sample buffer and denature for 10 min at 99 °C.

2.7.2. Load the sample onto an SDS-PAGE gel and run the gel for 1 h at 100 V.

2.7.3. Stain the gel overnight with Coomassie Brilliant Blue R-250 staining solution and destain during three consecutive washes (1 h/wash) with Coomassie Brilliant Blue R-250 destaining solution.

NOTE: Crude histones (**Figure 2**) can be compared with eluted and purified histones (*i.e.*, column input [**Figure 5A**]).

### **3. Purification of Core Histones**

#### **3.1. Spin column equilibration**

3.1.1. Add 500  $\mu$ L of equilibration buffer to each spin column being used. Do not touch the column membrane.

3.1.2. Centrifuge at 4 °C for 3 min at 800 x *g*. Discard the flow-through. Repeat 1x.

#### **3.2. Histone Purification**

3.2.1. Add 500  $\mu$ L of the sample of interest from step 2.6 to the column. Centrifuge at 4 °C for 3 min at 800 x *g*. Collect the flow-through.

3.2.2. Repeat the previous step as many times as necessary to load the entire sample onto the column. Do not overfill the spin column.

3.2.3. Combine the flow-through from each centrifugation step to analyze the column-binding efficiency (**Figure 3**).

3.2.4. Follow step 2.7 to analyze the column flow-through.

#### **3.3. Column wash**

3.3.1. Add 500  $\mu$ L of the wash buffer to each column. Centrifuge at 4 °C for 3 min at 800 x *g*. Collect the flow-through wash (wash #1).

3.3.2. Repeat step 3.3.1 for a total of three washes. Collect the flow-through washes #2 and #3. Do not pool the consecutive column flow-through washes.

3.3.3. To further evaluate the column's histone-binding efficiency, analyze the three column washes by following step 2.7 (**Figure 4**).

#### **3.4. Histone elution**

3.4.1. Transfer the column into a new labelled 1.5 mL tube.

3.4.2. Add 50  $\mu$ L of the histone elution buffer. Centrifuge at 4 °C for 3 min at 800 x *g*. Save the flow-through containing histone proteins.

3.4.3. For an additional elution, repeat step 3.4.2. Do not combine the first and second flow-through eluates as they differ in histone quantity and purity.

#### 4. Precipitation of Core Histones

4.1. Add perchloric acid (PCA) to the purified histones to a final concentration of 4% PCA (*e.g.*, add 3  $\mu$ L of 70% PCA to 50  $\mu$ L of purified histones from step 3.4.2).

4.2. Centrifuge for 3 s to collect all residual liquid from the tube wall. Mix by pipetting up and down 6x.

4.3. Place the tubes in a rack and incubate for 24 h at 4 °C.

4.4. The next day, prechill a microcentrifuge to 4 °C and centrifuge the samples for 75 min at maximum speed at 4 °C.

4.5. After the centrifugation is complete, a small white pellet containing precipitated histones will be visible on the bottom of the tube. Do not vortex the sample.

4.6. Carefully aspirate the supernatant and, without disturbing the pellet, add 500  $\mu$ L of ice-cold 4% PCA to the sample.

4.7. Centrifuge at 4 °C for 10 min at maximum speed. Carefully aspirate the supernatant.

4.8. Repeat step 4.7 2x.

4.9. Without disturbing the pellet, add 500  $\mu$ L of ice-cold acetone. Centrifuge at 4 °C for 10 min at maximum speed. Carefully aspirate the supernatant.

4.10. Repeat step 4.9 2x.

4.11. Carefully aspirate the supernatant, leave the tubes uncapped, and allow the sample to dry on ice for 30 min. Check if all residual acetone has evaporated.

4.12. Leave the tubes uncapped and allow the sample to dry at room temperature (RT) for 5 min.

4.13. Resuspend the pellet in 30  $\mu$ L of sterile water. Do not pipet up and down. Flick the tube gently with a finger.

4.14. Cap all tubes and allow the histones to reconstitute on ice for 30 - 50 min, depending on the pellet size. Check if the pellet is resuspended.

4.15. Cap all tubes and allow the pellet to further resuspend at RT for 5 min.

NOTE: This solution (first and second elution from step 3.4.3) is constituted of purified and desalted histones and may be used for further quantification and histone acetylation analysis.

## 5. Quantification of Eluted Histone Proteins

5.1. Use a spectrophotometer according to the manufacturer's protocol to quantify the total histone proteins obtained after the final elution in step 4.15. Measure the absorbance at 230 nm. Record the A260/A280 ratio indicative of the sample contamination with nucleic acid.

5.2. Use the following formula to calculate the histone concentration (x):

$$x \left[ \frac{\text{mg}}{\text{mL}} \right] = \frac{\text{OD} \times 1 \left[ \frac{\text{mg}}{\text{mL}} \right]}{0.42}$$

Here, OD is the optical density measured at A230 nm.

5.3. A histone concentration of ~1.5 mg/mL is considered an average yield for cell lines, while a histone concentration of ~5.0 mg/mL is considered an average yield for 30 mg of tissue.

## 6. Western Blot Analysis

6.1. Adjust the purified and eluted histone from step 4.15 to ~10 µg of histone protein/sample.

6.2. Add the appropriate volume of water and 4x Laemmli sample buffer to adjust the loading volumes.

6.3. Denature the samples for 10 min at 99 °C. Cool them on ice. Centrifuge for 3 s to collect all residual liquid and condensation from the tube wall.

6.4. Load the samples onto an SDS-PAGE gel and run the gel for 1 h at 100 V.

6.5. To visualize total histone protein, stain the gel overnight with Coomassie Brilliant Blue R-250 staining solution and destain during three consecutive washes (1 h/wash) with Coomassie Brilliant Blue R-250 destaining solution.

NOTE: The first elution of histone proteins contains high-quality histones (**Figure 5A**) while the second elution contains low to no levels of histones (**Figure 5B**).

6.6. To quantify histone PTMs, use a transfer system (see **Table of Materials**) to transfer the histone protein from the SDS-PAGE gel (step 6.4) onto a PVDF membrane.

6.6.1. To assemble the transfer sandwich, open the transfer system cassette and place the PVDF membrane stack (labelled as **Bottom+**) on the bottom of the cassette with the membrane facing



up. Roll the membrane gently with a blot roller to remove any air from between the stack and the membrane.

6.6.2. Lay the gel on top of the membrane, roll the gel gently with a blot roller to remove any air from between the membrane and the gel, and place the top stack on the gel. Roll gently again and place the cassette cover on top of the sandwich, press down firmly, and turn the knob clockwise to lock.

6.6.3. Insert the cassette to the transfer system slot. On the apparatus screen, select **Turbo Protocol**. Use a 3 min protocol for a single mini gel or a 7 min protocol for more than two mini gels.

6.6.4. Stain the membrane with Ponceau S stain for 5 min and visualize the total histone proteins.

6.6.5. Wash them in 1x Tris-buffered saline (TBS) with 0.1% Tween 20 for 2 h and block them in 5% milk for 1 h. Incubate with primary and secondary antibody (overnight at 4 °C or 1 h at RT, respectively) or according to a previously optimized protocol.

NOTE: In the current protocol, antibodies against acetylated histones H4K12 (**Figure 6** and **Figure 7**) and H3K27 (**Figure 8**) were used.

#### **REPRESENTATIVE RESULTS:**

To illustrate the progression of the histone purification protocol and composition of all analyzed fractions, we evaluated different histone extracts from human microglial BV2 cells. To demonstrate the quantification of histones H3 and H4 PTMs (*i.e.*, acetylation), we used brain tissue lysates.

BV2 cells were plated at  $5 \times 10^6$  cells per dish in 10 cm tissue culture-treated dishes and allowed to grow to confluency for 48 h. Cells were then collected, and histones were released from chromatin by an incubation in extraction buffer containing 0.4 M sulfuric acid, 1 mM KCl, 1 mM  $\text{MgCl}_2$ , 50 mM Tris-HCl (pH 8.0), and 1x protease inhibitor. The extraction time, between 15 min and 24 h, did not affect the overall composition of crude histone extracts as determined by Coomassie Brilliant Blue staining (**Figure 2**). Next, crude histones were passed through the equilibrated histone columns and the flow-through was analyzed. High column-binding efficiency is determined by the absence of histone protein in the flow-through when analyzed by Coomassie Brilliant Blue staining. We determined the column-binding efficiency to be 100% as there were no detectable histone proteins present in the analyzed flow-through (**Figure 3**). All membranes with bound histones were then washed three times with wash buffer to remove any remaining impurities, leaving only histone proteins bound to the silica gel. We determined that, for all histone extraction times (*i.e.*, 15 min, 2 h, and 24 h), the first membrane wash was the most important to remove nonhistone contaminations from the columns, while the second and third washes did not influence the sample purity. Thus, depending on the sample type, the last two washes might be omitted. Following the first elution of histone protein from the column (using elution buffer containing 1mM NaCl and EDTA), histones were precipitated overnight with 4%

perchloric acid and then pelleted, washed, and analyzed for the enrichment of purified histones H3 and H4. We observed that 24 h of extraction time increases the amount of H3 and H4 histones in the purified fraction compared to 15 min and 2 h of extraction time (**Figure 5A**). The second elution from the column did not result in high-quality or high-quantity histones (**Figure 5B**).

Next, we used brain tissue homogenates to quantify histone H3 and H4 PTMs, namely acetylation. Wild-type (C57BL6/J) male mice were administered a broadly acting HDAC inhibitor (tributyrin) at a dose of 5 g/kg orally for 3 d. Whole-brain tissue was collected on day 4 and crude histones were extracted according to the described protocol. Using an unpaired *t*-test, we determined that tributyrin increases the acetylation of histones in the crude extract ( $t(6) = 6.184$ ,  $P = 0.0004$ ); however, impurities are detected in the extract (the histone bands are not clearly defined). Thus, H4K12ac antibody does not have a high specificity (**Figure 6**). To further evaluate the applicability of the presented protocol to smaller tissue sections, we collected the prefrontal cortex from triple transgenic Alzheimer's disease (3 x Tg-AD) mice treated daily with 10 mg/kg M344, a class I and IIb HDAC inhibitor, for four months. Histone purification and precipitation was performed according to the herein described protocol. Using the purified histone H3 and H4 fraction, we determined that M344 increases H4K12 acetylation 2.4-fold ( $t(6) = 13.03$ ,  $P < 0.0001$ ), with a high specificity of H4K12ac antibody (**Figure 7**). Similarly, we observed an increase in histone H3 acetylation in BV2 cells in response to another HDAC inhibitor, namely the selective HDAC3 inhibitor, RGFP-966. 10  $\mu$ M of RGFP-966 causes an approximately twofold increase of acetylation at histone H3K27 after 24 h of treatment. Student's unpaired *t*-test was used to compare control *versus* treated cells.

#### FIGURE AND TABLE LEGENDS:

**Figure 1: Timeline of the histone purification protocol.** All steps for histone analyses are shown below along with the estimated time needed for each step. Figures depicting the outcome of particular steps and presented within the manuscript are referred to in parentheses.

**Figure 2: Representative Coomassie Brilliant Blue-stained gel demonstrating crude histones extracted from BV2 cells.** BV2 cells were cultured for 48 h before the histone extraction protocol began. Crude histones were extracted for 15 min, 2 h, and 24 h, with three replicates for each time point (this is also the case in **Figure 3**, **Figure 4**, and **Figure 5**). Both nonhistone and histone proteins are present in the crude histone extract.

**Figure 3: Representative Coomassie Brilliant Blue-stained gel demonstrating column flow-through following histone purification steps from BV2 cells.** Following crude histone passing through the histone binding column, only nonhistone proteins are present in the flow-through. Histone proteins are absent in this fraction.

**Figure 4: Representative Coomassie Brilliant Blue-stained gel demonstrating a column wash following a histone purification step from BV2 cells.** Regardless of the histone extraction times, which were (A) 15 min, (B) 2 h, or (C) 24 h, low quantities of nonhistone proteins were only present in the first-wash histone binding column. Histone proteins were absent in all washes.

**Figure 5: Representative Coomassie Brilliant Blue-stained gel demonstrating elutions following a histone purification step from BV2 cells.** (A) High-quality purified and desalted histone H3 and H4 were detected after the first elution from the histone purification column. (B) The second elution from the histone purification column did not yield a high quality or quantity of histones H3 or H4.

**Figure 6: The broadly acting HDAC inhibitor, tributyrin, increases H4K12 acetylation in the whole brain of wild-type mice.** (A) This panel shows a representative western blot depicting an increase of H4K12 acetylation in the crude histone extract collected from the whole brain of wild-type mice in response to the broadly acting HDAC inhibitor, tributyrin. (B) This panel shows the quantification of the increase in H4K12 acetylation *in vivo*. Unpaired *t*-test was used to compare groups ( $t(6) = 6.076$ ,  $P = 0.0005$ ). The bars represent the mean  $\pm$  the standard error of the mean (SEM).  $N = 8$ . \*\*\* $P < 0.0001$ .

**Figure 7: The class I and IIb HDAC inhibitor, M344, increases H4K12 acetylation in the prefrontal cortex of triple transgenic Alzheimer's disease (3 x Tg-AD) mice.** (A) This panel shows a representative western blot depicting an increase of H4K12 acetylation in the purified and desalted histone extract collected from the prefrontal cortex of 3 x Tg-AD mice in response to the inhibition of HDACs by M344. (B) This panel shows the quantification of the increase of H4K12 acetylation in response to M344 administered at a 10 mg/kg daily dose for four months. Unpaired *t*-test was used to compare groups ( $t(6) = 13.30$ ,  $P < 0.0001$ ). The bars represent the mean  $\pm$  the SEM.  $N = 8$ . \*\*\*\* $P < 0.00001$ .

**Figure 8: The selective HDAC3 inhibitor, RGFP-966, increases H3K27 acetylation in BV2 microglial cells.** (A) This panel shows a representative western blot depicting an increase of H3K27 acetylation in the purified and desalted histone extract collected from BV2 cells in response to the HDAC3 inhibition by RGFP-966. (B) RGFP-966 causes an approximately twofold increase of acetylation at histone H3 and lysine (K) 27 after 24 h of treatment. Unpaired *t*-test was used to compare control *versus* treated cells ( $t(4) = 5.981$ ,  $P = 0.002$ ). The bars represent the mean  $\pm$  the SEM.  $N = 6$ . \*\* $P < 0.01$ .

**Table 1: Optimized condition for brain tissue homogenization.**

## DISCUSSION:

In the current work, we demonstrated an optimized method to purify core histone proteins and quantify histone H3 and H4 PTMs (*e.g.*, acetylation). The presented protocol is a comprehensive workflow that incorporates optimized procedures regarding cells and brain tissue preparation, crude histone purification, and detailed histone precipitation, elution, and quantification, which are followed by histone electrophoresis and robust histone PTM quantification. The large amount of details provided here allows for a replicable generation of high-quality data, despite the need for lengthy manipulations of the histone samples.

Many currently published protocols require the use of HPLC to isolate pure fractions of histones H3 and H4<sup>19</sup>. Although HPLC is a powerful technique, its complexity and low-throughput deter most molecular biologists and nonexperts from its frequent use. Indeed, HPLC is not available to many labs, and highly-skilled personnel is required to operate the instrument. HPLC is oftentimes time-consuming, expensive, and potentially hazardous. Presented here is an inexpensive, medium-throughput strategy to achieve results of similar quality which bypasses HPLC. The reported strategy is also more practical and suitable for use in almost any lab as it uses a simple spin column approach that does not require specialized instrument operation skills. Additionally, histone H3/H4 tetramer is extracted as a single, pure, and abundant fraction, enabling a reliable quantification of preserved PTMs on each of the proteins.

PTMs are extremely sensitive to changes in oxidative stress and changes in pH<sup>20,21</sup>. Thus, in contrast to previously published methods<sup>18</sup>, we report an efficient strategy of rinsing the cells in serum-free media to ensure a minimum metabolic disturbance of the cells and to avoid the interference of the native PTMs with serum components. The current protocol not only bypasses the traditional nuclei isolation but also provides optimal times for cell lysis and the exact tissue homogenization procedure that allows for the preservation of the nuclear envelope while avoiding nuclear aggregation. Although the extraction time can be manipulated based on the number of cells, the cell type used, the tissue size, *etc.*, extended lysis is not desirable as it might lead to the lysis of the nuclei and DNA release, making the sample difficult to handle. Importantly, multiple checkpoints within the protocol exist for the validation of successful histone purification (*e.g.*, steps 2.7 and 3.2.3). This strategy also facilitates troubleshooting throughout the lengthy procedure.

Another important and unique feature of the presented protocol is its full compatibility with downstream western blot analysis tools and others if so desired. Histone proteins are detected at ~15 kDa<sup>13,22</sup> and, similarly to other small molecular weight proteins, have been proven challenging to detect by standard immunoblotting techniques. The use of a high-performance and high-throughput transfer system in combination with optimal resolution protein gels allows for the maintenance of protein native confirmation (in the absence of SDS) and activity in the absence of SDS and high transfer efficiency of the low molecular weight histone proteins, thus assuring a reliable histone PTM quantification.

#### **ACKNOWLEDGMENTS:**

The authors express their gratitude to the Florida Department of Health Ed and Ethel Moore Alzheimer's Research Program (grants 6AZ08 and 7AZ26), the NIH-NIAAA (grant 5R01AA023781-03), and the American Heart Association (grant 17PRE33660831).

#### **DISCLOSURES:**

The authors have nothing to disclose.

#### **REFERENCES:**

1. Holliday R. Is there an Epigenetic Component in Long-term Memory? *Journal of Theoretical Biology*. **200**, 339-341 (1999).

2. DeWoskin, V.A., Million, R.P. The epigenetics pipeline. *Nature Reviews Drug Discovery*. **12**, 661-662 (2013).
3. Eberharter, A., Becker, P.B. Histone acetylation: a switch between repressive and permissive chromatin. *EMBO Reports*. **3**, 224-229 (2002).
4. Grunstein, M. Histone acetylation in chromatin structure and transcription. *Nature*. **389**, 349-352 (1997).
5. Sartor, G.C., Powell, S.K., Brothers, S.P., Wahlestedt, C. Epigenetic Readers of Lysine Acetylation Regulate Cocaine-Induced Plasticity. *The Journal of Neuroscience*. **35**, 15062-15072 (2015).
6. Komatsu, N. *et al.* SAHA, a HDAC inhibitor, has profound anti-growth activity against non-small cell lung cancer cells. *Oncology Reports*. **15**, 187-191 (2006).
7. Bahari-Javan, S., Sananbenesi, F., Fischer, A. Histone-acetylation: a link between Alzheimer's disease and post-traumatic stress disorder? *Frontiers in Neuroscience*. **8**, 160 (2014).
8. Roh, T.-Y., Cuddapah, S., Zhao, K. Active chromatin domains are defined by acetylation islands revealed by genome-wide mapping. *Genes & Development*. **19**, 542-552 (2005).
9. Mutskov, V., Felsenfeld, G. Silencing of transgene transcription precedes methylation of promoter DNA and histone H3 lysine 9. *The EMBO Journal*. **23**, 138-149 (2004).
10. Howe, L., Brown, C.E., Lechner, T., Workman, J.L. Histone acetyltransferase complexes and their link to transcription. *Critical Reviews in Eukaryotic Gene Expression*. **9**, 231-243 (1999).
11. Jenuwein, T., Allis, C.D. Translating the histone code. *Science*. **293**, 1074-1080 (2001).
12. Bowman, G.D., Poirier, M.G. Post-Translational Modifications of Histones That Influence Nucleosome Dynamics. *Chemical Reviews*. **115**, 2274-2295 (2015).
13. Volmar, C.-H., Wahlestedt, C. Histone deacetylases (HDACs) and brain function. *Neuroepigenetics*. **1**, 20-27 (2015).
14. Plagg, B., Ehrlich, D., Kniewallner, K.M., Marksteiner, J., Humpel, C. Increased Acetylation of Histone H4 at Lysine 12 (H4K12) in Monocytes of Transgenic Alzheimer's Mice and in Human Patients. *Current Alzheimer Research*. **12**, 752-760 (2015).
15. Bhaskara, S. *et al.* Hdac3 is essential for the maintenance of chromatin structure and genome stability. *Cancer Cell*. **18**, 436-447 (2010).

16. Mottamal, M., Zheng, S., Huang, T.L., Wang, G. Histone Deacetylase Inhibitors in Clinical Studies as Templates for New Anticancer Agents. *Molecules*. **20**, 3898-3941 (2015).
17. Ramakrishnan, S. *et al.* HDAC 1 and 6 modulate cell invasion and migration in clear cell renal cell carcinoma. *BMC Cancer*. **16**, 617 (2016).
18. Wapenaar, H., Dekker, F.J. Histone acetyltransferases: challenges in targeting bi-substrate enzymes. *Clinical Epigenetics*. **8**, 59 (2016).
19. Klinker, H., Haas, C., Harrer, N., Becker, P.B., Mueller-Planitz, F. Rapid Purification of Recombinant Histones. *PLoS ONE*. **9**, e104029 (2014).
20. Chen, K. *et al.* Neurodegenerative Disease Proteinopathies Are Connected to Distinct Histone Post-translational Modification Landscapes. *ACS Chemical Neuroscience*. **9**, 838-848 (2018).
21. Simithy, J., Sidoli, S., Garcia, B.A. Integrating Proteomics and Targeted Metabolomics to Understand Global Changes in Histone Modifications. *Proteomics*. e1700309 (2018).
22. Volmar, C.-H. *et al.* An Epigenetic Approach for the Modulation of Amyloid Precursor Protein (APP) Processing and Improvement of Memory in Alzheimer's Disease. *Neuropsychopharmacology: official publication of the American College of Neuropsychopharmacology*. **40**, S470 (2015).

Figure 1




Figure 2

[Click here to access/download;Figure;Fig. 2. Crude histones\\_JoVE.pdf](#) 






Figure 3

[Click here to access/download;Figure;Fig. 3. Flow-through\\_JoVE.pdf](#) 




Figure 4

[Click here to access/download;Figure;Fig. 4. Wash\\_JoVE.pdf](#)




Figure 5

[Click here to access/download;Figure;Fig. 5. Purified histones\\_JoVE.pdf](#)





Figure 6






Figure 7

**A**



**B**

H4K12ac - prefrontal cortex  
(purified histone extract)






Figure 8



Representative tissue (one hemisphere) *	Average tissue weight (mg)	Extraction Buffer (mL)	Number of strokes
Mouse cerebellum	40	1	40
Mouse frontal cortex	30	0.3	20
Mouse hippocampus	27	0.3	18
Mouse entorhinal cortex	19	0.3	17

\* All experiments were performed on adult male mice.  
Average age: 16 months. Average weight: 30 grams.

Name of Material/ Equipment	Company	Catalog Number	Comments/Description
1.5 mL microcentrifuge tubes	ThermoFiser Scientific	05-408-129	or equivalent from other sources
Sterile water	Gibco	15-230-204	or equivalent from other sources
70% perchloric acid	Sigma Aldrich	311421	or equivalent from other sources
100% acetone	Sigma Aldrich	270725	or equivalent from other sources
pH-indicator strips, non-bleeding	Millipore Sigma	1095310001	
4x SDS sample buffer	BIO-RAD	161-0747	
Benchtop rotor	Cole-Parmer	UX-04397-34	or equivalent from other sources
1.5 mL tube rack	ThermoFiser Scientific	05-541	or equivalent from other sources
Histone purification mini kit	Active Motif	40026	spin columns included in the kit
Protease Inhibitor Cocktail	ThermoFiser Scientific	78430	or equivalent from other sources
Nanodrop instrument	ThermoFiser Scientific	ND-2000	
Tissue culture dishes	VWR	10062-880	required for histone extraction from cultured cells
Tissue culute media	varies based on cell line used		
Low-serum media	ThermoFiser Scientific	51985091	
Plastic cell scraper	Falcon	353086	
SDS-PAGE gradient gel	BIO-RAD	456-9035	
Coomassie Brilliant Blue R-250 Staining Solution	BIO-RAD	1610436	
Coomassie Brilliant Blue R-250 Destaining Solution	BIO-RAD	1610438	
Trans-Blot Turbo Mini PVDF Transfer Packs	BIO-RAD	1704156	
Trans-Blot Turbo Transfer System	BIO-RAD	1704150	
Ponceau S stain	CellSignalling	59803S	
Dounce homogenizer (size/cap sc 7mL) with a small size clearance	Kimble Chase	885302-0007	required for histone extraction from tissues
100% bleach	Clorox	68973	
H4K12ac antibody	Active Motif	39166	required for PTMs quantification via WB
H3K27ac antibody	Active Motif	39134	





1 Alewife Center #200  
Cambridge, MA 02140  
tel. 617.945.9051  
www.jove.com

## ARTICLE AND VIDEO LICENSE AGREEMENT

Title of Article:	Purification of core histones and quantification of acetylated histone marks in cells and brain tissue
Author(s):	Karolina J. Janczura, Claude-Henry Volmar and Claes Wahlestedt

Item 1: The Author elects to have the Materials be made available (as described at <http://www.jove.com/publish>) via:

☐ Standard Access

☒ Open Access

Item 2: Please select one of the following items:

- ☒ The Author is **NOT** a United States government employee.
- ☐ The Author is a United States government employee and the Materials were prepared in the course of his or her duties as a United States government employee.
- ☐ The Author is a United States government employee but the Materials were NOT prepared in the course of his or her duties as a United States government employee.

### ARTICLE AND VIDEO LICENSE AGREEMENT

1. **Defined Terms.** As used in this Article and Video License Agreement, the following terms shall have the following meanings: **"Agreement"** means this Article and Video License Agreement; **"Article"** means the article specified on the last page of this Agreement, including any associated materials such as texts, figures, tables, artwork, abstracts, or summaries contained therein; **"Author"** means the author who is a signatory to this Agreement; **"Collective Work"** means a work, such as a periodical issue, anthology or encyclopedia, in which the Materials in their entirety in unmodified form, along with a number of other contributions, constituting separate and independent works in themselves, are assembled into a collective whole; **"CRC License"** means the Creative Commons Attribution-Non Commercial-No Derivs 3.0 Unported Agreement, the terms and conditions of which can be found at: <http://creativecommons.org/licenses/by-nc-nd/3.0/legalcode>; **"Derivative Work"** means a work based upon the Materials or upon the Materials and other pre-existing works, such as a translation, musical arrangement, dramatization, fictionalization, motion picture version, sound recording, art reproduction, abridgment, condensation, or any other form in which the Materials may be recast, transformed, or adapted; **"Institution"** means the institution, listed on the last page of this Agreement, by which the Author was employed at the time of the creation of the Materials; **"JoVE"** means MyJoVE Corporation, a Massachusetts corporation and the publisher of The Journal of Visualized Experiments; **"Materials"** means the Article and / or the Video; **"Parties"** means the Author and JoVE; **"Video"** means any video(s) made by the Author, alone or in conjunction with any other parties, or by JoVE or its affiliates or agents, individually or in collaboration with the Author or any other parties, incorporating all or any portion

of the Article, and in which the Author may or may not appear.

2. **Background.** The Author, who is the author of the Article, in order to ensure the dissemination and protection of the Article, desires to have the JoVE publish the Article and create and transmit videos based on the Article. In furtherance of such goals, the Parties desire to memorialize in this Agreement the respective rights of each Party in and to the Article and the Video.

3. **Grant of Rights in Article.** In consideration of JoVE agreeing to publish the Article, the Author hereby grants to JoVE, subject to **Sections 4 and 7** below, the exclusive, royalty-free, perpetual (for the full term of copyright in the Article, including any extensions thereto) license (a) to publish, reproduce, distribute, display and store the Article in all forms, formats and media whether now known or hereafter developed (including without limitation in print, digital and electronic form) throughout the world, (b) to translate the Article into other languages, create adaptations, summaries or extracts of the Article or other Derivative Works (including, without limitation, the Video) or Collective Works based on all or any portion of the Article and exercise all of the rights set forth in (a) above in such translations, adaptations, summaries, extracts, Derivative Works or Collective Works and (c) to license others to do any or all of the above. The foregoing rights may be exercised in all media and formats, whether now known or hereafter devised, and include the right to make such modifications as are technically necessary to exercise the rights in other media and formats. If the "Open Access" box has been checked in **Item 1** above, JoVE and the Author hereby grant to the public all such rights in the Article as provided in, but subject to all limitations and requirements set forth in, the CRC License.

## ARTICLE AND VIDEO LICENSE AGREEMENT

4. **Retention of Rights in Article.** Notwithstanding the exclusive license granted to JoVE in **Section 3** above, the Author shall, with respect to the Article, retain the non-exclusive right to use all or part of the Article for the non-commercial purpose of giving lectures, presentations or teaching classes, and to post a copy of the Article on the Institution's website or the Author's personal website, in each case provided that a link to the Article on the JoVE website is provided and notice of JoVE's copyright in the Article is included. All non-copyright intellectual property rights in and to the Article, such as patent rights, shall remain with the Author.

5. **Grant of Rights in Video – Standard Access.** This **Section 5** applies if the "Standard Access" box has been checked in **Item 1** above or if no box has been checked in **Item 1** above. In consideration of JoVE agreeing to produce, display or otherwise assist with the Video, the Author hereby acknowledges and agrees that, Subject to **Section 7** below, JoVE is and shall be the sole and exclusive owner of all rights of any nature, including, without limitation, all copyrights, in and to the Video. To the extent that, by law, the Author is deemed, now or at any time in the future, to have any rights of any nature in or to the Video, the Author hereby disclaims all such rights and transfers all such rights to JoVE.

6. **Grant of Rights in Video – Open Access.** This **Section 6** applies only if the "Open Access" box has been checked in **Item 1** above. In consideration of JoVE agreeing to produce, display or otherwise assist with the Video, the Author hereby grants to JoVE, subject to **Section 7** below, the exclusive, royalty-free, perpetual (for the full term of copyright in the Article, including any extensions thereto) license (a) to publish, reproduce, distribute, display and store the Video in all forms, formats and media whether now known or hereafter developed (including without limitation in print, digital and electronic form) throughout the world, (b) to translate the Video into other languages, create adaptations, summaries or extracts of the Video or other Derivative Works or Collective Works based on all or any portion of the Video and exercise all of the rights set forth in (a) above in such translations, adaptations, summaries, extracts, Derivative Works or Collective Works and (c) to license others to do any or all of the above. The foregoing rights may be exercised in all media and formats, whether now known or hereafter devised, and include the right to make such modifications as are technically necessary to exercise the rights in other media and formats. For any Video to which this **Section 6** is applicable, JoVE and the Author hereby grant to the public all such rights in the Video as provided in, but subject to all limitations and requirements set forth in, the CRC License.

7. **Government Employees.** If the Author is a United States government employee and the Article was prepared in the course of his or her duties as a United States government employee, as indicated in **Item 2** above, and any of the licenses or grants granted by the Author hereunder exceed the scope of the 17 U.S.C. 403, then the rights granted hereunder shall be limited to the maximum

rights permitted under such statute. In such case, all provisions contained herein that are not in conflict with such statute shall remain in full force and effect, and all provisions contained herein that do so conflict shall be deemed to be amended so as to provide to JoVE the maximum rights permissible within such statute.

8. **Protection of the Work.** The Author(s) authorize JoVE to take steps in the Author(s) name and on their behalf if JoVE believes some third party could be infringing or might infringe the copyright of either the Author's Article and/or Video.

9. **Likeness, Privacy, Personality.** The Author hereby grants JoVE the right to use the Author's name, voice, likeness, picture, photograph, image, biography and performance in any way, commercial or otherwise, in connection with the Materials and the sale, promotion and distribution thereof. The Author hereby waives any and all rights he or she may have, relating to his or her appearance in the Video or otherwise relating to the Materials, under all applicable privacy, likeness, personality or similar laws.

10. **Author Warranties.** The Author represents and warrants that the Article is original, that it has not been published, that the copyright interest is owned by the Author (or, if more than one author is listed at the beginning of this Agreement, by such authors collectively) and has not been assigned, licensed, or otherwise transferred to any other party. The Author represents and warrants that the author(s) listed at the top of this Agreement are the only authors of the Materials. If more than one author is listed at the top of this Agreement and if any such author has not entered into a separate Article and Video License Agreement with JoVE relating to the Materials, the Author represents and warrants that the Author has been authorized by each of the other such authors to execute this Agreement on his or her behalf and to bind him or her with respect to the terms of this Agreement as if each of them had been a party hereto as an Author. The Author warrants that the use, reproduction, distribution, public or private performance or display, and/or modification of all or any portion of the Materials does not and will not violate, infringe and/or misappropriate the patent, trademark, intellectual property or other rights of any third party. The Author represents and warrants that it has and will continue to comply with all government, institutional and other regulations, including, without limitation all institutional, laboratory, hospital, ethical, human and animal treatment, privacy, and all other rules, regulations, laws, procedures or guidelines, applicable to the Materials, and that all research involving human and animal subjects has been approved by the Author's relevant institutional review board.

11. **JoVE Discretion.** If the Author requests the assistance of JoVE in producing the Video in the Author's facility, the Author shall ensure that the presence of JoVE employees, agents or independent contractors is in accordance with the relevant regulations of the Author's institution. If more than one author is listed at the beginning of this Agreement, JoVE may, in its sole

## ARTICLE AND VIDEO LICENSE AGREEMENT

discretion, elect not take any action with respect to the Article until such time as it has received complete, executed Article and Video License Agreements from each such author. JoVE reserves the right, in its absolute and sole discretion and without giving any reason therefore, to accept or decline any work submitted to JoVE. JoVE and its employees, agents and independent contractors shall have full, unfettered access to the facilities of the Author or of the Author's institution as necessary to make the Video, whether actually published or not. JoVE has sole discretion as to the method of making and publishing the Materials, including, without limitation, to all decisions regarding editing, lighting, filming, timing of publication, if any, length, quality, content and the like.

12. **Indemnification.** The Author agrees to indemnify JoVE and/or its successors and assigns from and against any and all claims, costs, and expenses, including attorney's fees, arising out of any breach of any warranty or other representations contained herein. The Author further agrees to indemnify and hold harmless JoVE from and against any and all claims, costs, and expenses, including attorney's fees, resulting from the breach by the Author of any representation or warranty contained herein or from allegations or instances of violation of intellectual property rights, damage to the Author's or the Author's institution's facilities, fraud, libel, defamation, research, equipment, experiments, property damage, personal injury, violations of institutional, laboratory, hospital, ethical, human and animal treatment, privacy or other rules, regulations, laws, procedures or guidelines, liabilities and other losses or damages related in any way to the submission of work to JoVE, making of videos by JoVE, or publication in JoVE or elsewhere by JoVE. The Author shall be responsible for, and shall hold JoVE harmless from, damages caused by lack of sterilization, lack of cleanliness or by contamination due to


the making of a video by JoVE its employees, agents or independent contractors. All sterilization, cleanliness or decontamination procedures shall be solely the responsibility of the Author and shall be undertaken at the Author's expense. All indemnifications provided herein shall include JoVE's attorney's fees and costs related to said losses or damages. Such indemnification and holding harmless shall include such losses or damages incurred by, or in connection with, acts or omissions of JoVE, its employees, agents or independent contractors.

13. **Fees.** To cover the cost incurred for publication, JoVE must receive payment before production and publication the Materials. Payment is due in 21 days of invoice. Should the Materials not be published due to an editorial or production decision, these funds will be returned to the Author. Withdrawal by the Author of any submitted Materials after final peer review approval will result in a US\$1,200 fee to cover pre-production expenses incurred by JoVE. If payment is not received by the completion of filming, production and publication of the Materials will be suspended until payment is received.

14. **Transfer, Governing Law.** This Agreement may be assigned by JoVE and shall inure to the benefits of any of JoVE's successors and assignees. This Agreement shall be governed and construed by the internal laws of the Commonwealth of Massachusetts without giving effect to any conflict of law provision thereunder. This Agreement may be executed in counterparts, each of which shall be deemed an original, but all of which together shall be deemed to be one and the same agreement. A signed copy of this Agreement delivered by facsimile, e-mail or other means of electronic transmission shall be deemed to have the same legal effect as delivery of an original signed copy of this Agreement.

A signed copy of this document must be sent with all new submissions. Only one Agreement is required per submission.

### CORRESPONDING AUTHOR

Name:	Claes Wahlestedt	
Department:	Psychiatry & Behavioral Sciences and Center for Therapeutic Innovation	
Institution:	University of Miami Miller School of Medicine	
Title:	Professor , Associate Dean, Vice Chair and Director	
Signature:		Date: 6/15/18

Please submit a **signed** and **dated** copy of this license by one of the following three methods:

1. Upload an electronic version on the JoVE submission site
2. Fax the document to +1.866.381.2236
3. Mail the document to JoVE / Attn: JoVE Editorial / 1 Alewife Center #200 / Cambridge, MA 02140



Claude-Henry Volmar, Ph.D.  
 Director, Research Laboratory, Center for Therapeutic Innovation  
 Associate Director, Sylvester Molecular Therapeutics Shared Resource  
 Department of Psychiatry and Behavioral Sciences  
 1501 NW 10<sup>th</sup> Avenue, BRB-433 [M-860]  
 Miami, FL 33136  
 Tel. 305-243-1209  
 cvolmar@med.miami.edu

September 4, 2018

Phillip Steindel, PhD  
 Review Editor  
 Journal of Visualized Experiments (JoVE)  
 Tel. 617-674-1888

Dear Dr. Steindel,

We thank you for the opportunity to resubmit our manuscript "Purification of H3 and H4 histone proteins and quantification of acetylated histone marks in cells and brain tissue" [JoVE58648R3]. We appreciate your constructive critiques. We are pleased to inform you that all issues have been addressed as follows:

- 1) The Protocol has been formatted according to JoVE guidelines and additional details required for filing have been added to the Protocol.
- 2) Figure 1 has been edited according to your recommendations and updated to include more details.
- 3) Statistical reporting has been revised throughout the entire document.
- 4) All questions brought up regarding manuscript presentation have been addressed.

Once again, thank you for your consideration of our manuscript and we look forward to a favorable review.

Sincerely,

Claude-Henry Volmar

## **Editor's comments:**

**1. 1.1.3: Please list what is in the Extraction buffer here. Also, assuming this is composed of the recipe given in the Results, what is the concentration of Tris-HCl and what is the protease inhibitor? The latter is not listed in the Table of Materials.**

The Components of the Extraction Buffer have been listed in step 1.1.3 and the concentration of Tris-HCl has been added to the list of the Buffer components. Information regarding Protease Inhibitor has been added to the Table of Materials.

**2. 3.1: Are the spin columns part of the purification kit listed in the Table of Materials? Please make this explicit if so.**

Correct, the spin columns are part of the purification kit listed in the Table of Materials. This information has been added to the Table of Materials in the "Comments/Description" column.

**3. 3.3.2/4.8: Does the 'this step' refer to the previous step (3.3.1/4.7, respectively)?**

Correct, 'this step' in steps 3.3.2/4.8 refers to the previous steps, *i.e.* steps 3.3.1 and 4.7. The wording has been changed to clarify which step needs to be repeated.

**4. 4.14-4.15/Figure 1: "Elute" seems to be the wrong word here; perhaps something like 'reconstitute'?**

The word "elute" has been substituted with "resuspend" in steps 4.14. and 4.15.

**5. 4.1.5: What do you mean by 'must be used for further quantification'?**

The meaning of the sentence is that the final product of the extraction, *i.e.* purified and desalted histones, and not crude histones from previous steps should be used for histone quantification and analysis. The sentence has been reworded to convey the main point.

**6. 6.6.1: There isn't really enough detail here for filming.**

More details have been added to step 6.6.1. Please see steps 6.6.1 – 6.6.3 in the revised version of the protocol.

**7. Formatted according to JoVE guidelines (spaces between all steps, all text aligned to the left margin), there is approximately 3.5 pages of the Protocol highlighted. Please shorten the highlighted portion to 2.75 pages or fewer, to fit within our limits for filming time and video length. Please do not highlight anything outside of the Protocol section (those are dealt with separately).**

The Protocol has been formatted according to the recommendation and the highlighted portion of the manuscript (only within the Protocol section) has been shortened.

**8. Results: In the discussion of Figure 6, you say that impurities are detected in the extract-how does Figure 6 show this?**

Purified and desalted histone H3 and H4 are detected on a PVDF membrane as two fine bands at ~15kDa (Figure 7A, histone H4, top blot; Figure 8A, histone H3, top blot; Figures 7A and 8A, histones H3 and H4, bottom blots). Considering high specificity of the antibodies used, impurities present in the crude histone preparation are visible on the top and bottom blots in Figure 6A as the histone bands are not clearly defined.

**9. Figure 1: There are some discrepancies between this and the protocol:**

**a) Crude extraction time is listed as 2 hours, but you include several options in the protocol.**

The optimal extraction time is between 15 min and 24h. In the current protocol, we demonstrate results following 15 min, 2 h and 24 h of extraction. It is recommended that several extraction times be tested for cell lines other than the ones presented in the current protocol. This information is included in the manuscript (step 2.1. – “Note”) and has been added to the legend of Figure 1.

**b) Centrifugation happens before the optional stopping point in the protocol, but after here.**

Centrifugation step (2.2.) must happen after the extraction step (2.1) and before optional stopping point (2.4). This information has been outlined correctly in Figure 1.

**c) Histone precipitation is done overnight (so, potentially as little as 16 hours) in the protocol, but listed as a full 24 hours here.**

It is recommended that histones are allowed to precipitate for 24 hours. This information has been clarified in the protocol (step 4.3.)

**d) Histone centrifugation is done for 1 h 15 min in the protocol, but for 1 h here.**

Centrifugation step is done for 1h 15min. This information has been outlined correctly in Figure 1.

**e) Histone wash appears to take ~1 h in the protocol (6 washes of 10 minutes each), but 45 min here.**

Histone wash steps last about 1h. This information has been outlined correctly in Figure 1.

**NOTE:** Figure 1 has been edited and updated to include more step-by-step protocol details.

**10. Figures 2-8: All of these appear to have multiple replicates (3 for Figures 2-5 and 8 and 2 for Figures 6-7) that are not explained in the figure legends.**

Sample size has been added to the legend of Figure 2-8. Statistical analysis and reporting has been revised throughout the manuscript.

**11. Figures 6-7: n/N appears to have changed between drafts-they were 8 before.**

The clerical error has been corrected. N= 4 per treatment group for Figures 6 and 7. N= 3 per treatment group for Figure 8.

**12. Figures 6-8. If n/N are indeed 6, why are you using 6 degrees of freedom for your t-tests, then; shouldn't it be 4?**

N= 4 per treatment group for Figures 6 and 7. There are two treatment groups, thus degrees of freedom for t – test equal 6. N= 3 per treatment group for Figure 8. There are two treatment groups, thus degrees of freedom for t – test equal 4.